BioXcel Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2017 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
BioXcel Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2017 to Q4 2023.
  • BioXcel Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $174M, a 46.7% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $174M +$55.3M +46.7% Dec 31, 2023 10-K 2024-03-22
Q4 2022 $118M +$46.5M +64.6% Dec 31, 2022 10-K 2024-03-22
Q4 2021 $71.9M +$30.2M +72.3% Dec 31, 2021 10-K 2023-03-16
Q4 2020 $41.7M +$26.5M +174% Dec 31, 2020 10-K 2022-03-11
Q4 2019 $15.3M +$8.99M +144% Dec 31, 2019 10-K 2021-03-12
Q4 2018 $6.26M +$5.1M +441% Dec 31, 2018 10-K 2020-03-09
Q4 2017 $1.16M Dec 31, 2017 10-K 2019-03-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.